Ozempic Response Varies by 20%+ Weight Loss Gap as Early Progress Beats Genetic Tests
Updated
Updated · creators.yahoo.com · Jun 6
Ozempic Response Varies by 20%+ Weight Loss Gap as Early Progress Beats Genetic Tests
3 articles · Updated · creators.yahoo.com · Jun 6
Summary
Weight loss on Ozempic-class drugs can range from under 5% of body weight—or even gain—to well above 20%, with Dr. Anthony Puopolo saying behavior, sex and diabetes status help explain the spread.
A loss of at least 5 pounds in the first 3 months is the strongest practical predictor of longer-term success, outperforming any known genetic marker now available.
Genetic findings still matter: Stanford-linked research found variants in about 1 in 10 people that may blunt GLP-1 effects, but Puopolo said a clinically useful pre-treatment test remains 5 to 10 years away.
Clinical patterns already offer guidance—women tend to lose more than men, people with Type 2 diabetes somewhat less, and emotional eaters may need added support such as CBT, stress management or other drugs.
The broader takeaway is that GLP-1s should be managed as long-term cardiometabolic therapy, not a one-off weight-loss fix, with weight regain of roughly 75% within a year after stopping.
Beyond Ozempic: Are gene therapies the answer for the millions of people with a genetic resistance to weight-loss drugs?
Why do blockbuster weight-loss drugs fail for 1 in 10 people? Scientists have finally found a genetic answer.
Landmark Study Reveals 10% of Population Genetically Resistant to GLP-1 Drugs, Urging Shift to Precision Medicine
Overview
A major Stanford-led study published in 2026 revealed that about 10% of people carry specific genetic variants in the PAM gene, which encodes the enzyme peptidyl-glycine alpha-amidating monooxygenase (PAM). This enzyme is crucial for activating hormones like GLP-1 through a process called amidation, which increases their potency. The identified genetic variants reduce the effectiveness of GLP-1 drugs by lowering PAM activity, making these medications less effective for some individuals. This discovery highlights the importance of personalized treatment approaches for diabetes and obesity, as not everyone responds the same way to GLP-1 therapies.